Global Ipilimumab Market, By Type (PD – L1 Antagonists, CTLA4 Antagonists, Immunocheckpoint Inhibitors, Other), Application (Cancer, Melanoma, Others), Mechanism of Action (Antibody-Dependent Cell Cytotoxicity, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors, T Lymphocyte Stimulants), Dosage (Liquids, Injectables, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the ipilimumab? market is anticipated to grow rapidly during the forecast period owing to the increasing prevalence of cancer. As per the International Agency for Research on Cancer (IARC), the global burden of cancer is anticipated to increase to 27.5 million new cases along with 16.3 million deaths by 2040. Melanoma is a type of skin cancer which occurs due to high exposure to ultraviolet (UV) light resulting in blistering sunburns. Ipilimumab is a monoclonal antibody that targets the anti-cytotoxic T-lymphocyte antigen (CTLA)-4. It is licensed in the United States for the first- or second-line treatment of individuals with malignant melanoma.
Data Bridge Market Research analyses that the ipilimumab? market was valued at USD 2.026 million in 2021 and is expected to reach USD 4.34 million by 2029, registering a CAGR of 10.0% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Ipilimumab is an immunotherapy drug used to treat cancer. Immunotherapy is systemic, which means that the therapies go through the bloodstream to all sections of your body. Cancers that have spread from their original site to various sections of the body are treated with systemic cancer therapy. Ipilimumab works by inhibiting a protein that prevents your immune system from attacking cancer cells correctly. It aids in the detection and elimination of cancer cells by your immune system.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (PD – L1 Antagonists, CTLA4 Antagonists, Immunocheckpoint Inhibitors, Other), Application (Cancer, Melanoma, Others), Mechanism of Action (Antibody-Dependent Cell Cytotoxicity, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors, T Lymphocyte Stimulants), Dosage (Liquids, Injectables, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (UK), Sanofi (France), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (US), Incyte (US), Baxter (US)
|
|
Market Opportunities
|
|
Ipilimumab? Market Dynamics
Drivers
- Increasing prevalence of cancer
The rising prevalence of cancer is a primary driver of the ipilimumab? market's growth.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of ipilimumab? market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the ipilimumab? market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of ipilimumab? market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the ipilimumab? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the ipilimumab? market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the ipilimumab? market. Additionally, strict guidelines as well as regulations and side effects of ipilimumab? such as headache, nausea, anemia, fatigue and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This ipilimumab? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ipilimumab? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Ipilimumab? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Ipilimumab? Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The ipilimumab market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the ipilimumab market's revenue trajectory.
Recent Development
- In November 2021, Bristol-Myers Squibb Company had received the U.S. Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA's Real-Time Oncology Examine (RTOR) pilot programme was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.
Global Ipilimumab? Market Scope
The ipilimumab? market is segmented on the basis of type, application, mechanism of action, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- PD – L1 Antagonists
- CTLA4 Antagonists
- Immunocheckpoint Inhibitors
- Other
On the basis of type, the global hepatic drugs market is segmented into PD – L1 antagonists, CTLA4 antagonists, immunocheckpoint inhibitors, and other.
Application
- Cancer
- Melanoma
- Others
On the basis of application, the global hepatic drugs market is segmented into cancer, melanoma and others.
Mechanism of Action
- Antibody-Dependent Cell Cytotoxicity
- Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
- T Lymphocyte Stimulants
On the basis of mechanism of action, the global hepatic drugs market is segmented into antibody-dependent cell cytotoxicity, cytotoxic T-lymphocyte antigen 4 inhibitors, and T lymphocyte stimulants.
Dosage
- Liquids
- Injectables
- Others
On the basis of dosage, the ipilimumab? market is segmented into liquids, injectables and others.
Route of Administration
- Intravenous
- Others
The route of administration segment for the ipilimumab? market is segmented into intravenous and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the ipilimumab? market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the ipilimumab? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Ipilimumab? Market Regional Analysis/Insights
The Ipilimumab? market is analysed and market size insights and trends are provided by country, type, application, mechanism of action, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Ipilimumab? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the ipilimumab? market because of the growing prevalence rate if cancer in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Ipilimumab? Market Share Analysis
The Ipilimumab? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ipilimumab? market.
Some of the major players operating in the ipilimumab? market are:
- AstraZeneca (UK)
- Sanofi (France)
- Bristol-Myers Squibb Company (US)
- Gilead Sciences, Inc. (US)
- Merck KGaA (Germany)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (US)
- Incyte (US)
- Baxter (US)
SKU-